Why the study?
Does the ACB scale better predict adverse clinical outcomes compared to other anticholinergic burden scales in older adults?
Does the ACB scale better predict adverse clinical outcomes compared to other anticholinergic burden scales in older adults?
The ACB scale may be a helpful tool for primary care and geriatrics clinicians to identify older adults at high risk for adverse outcomes due to anticholinergic burden.
This is the authors' abstract. We don't add key points for this paper.
Compared with the 2 other scales studied, the ACB shows good dose-response relationships between anticholinergic burden and a variety of adverse outcomes in older adults. For primary care and geriatrics clinicians, the ACB may be a helpful tool for identifying high-risk populations for interventions.
ACB may aid risk stratification in older adults; leaves open prospective validation of superiority over other scales.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2017) studied this question.